BEACHBODY CO INC/THE (BODI) Fundamental Analysis & Valuation

NASDAQ:BODI • US0734633094

Current stock price

11.635 USD
+0.47 (+4.26%)
Last:

This BODI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. BODI Profitability Analysis

1.1 Basic Checks

  • BODI had negative earnings in the past year.
  • BODI had a positive operating cash flow in the past year.
  • BODI had negative earnings in each of the past 5 years.
  • In multiple years BODI reported negative operating cash flow during the last 5 years.
BODI Yearly Net Income VS EBIT VS OCF VS FCFBODI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • BODI has a Return On Assets (-1.95%) which is in line with its industry peers.
  • BODI has a Return On Equity (-9.13%) which is in line with its industry peers.
  • Looking at the Return On Invested Capital, with a value of 10.47%, BODI is in the better half of the industry, outperforming 79.45% of the companies in the same industry.
Industry RankSector Rank
ROA -1.95%
ROE -9.13%
ROIC 10.47%
ROA(3y)-32.71%
ROA(5y)-35.55%
ROE(3y)-149.3%
ROE(5y)-119.79%
ROIC(3y)N/A
ROIC(5y)N/A
BODI Yearly ROA, ROE, ROICBODI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

1.3 Margins

  • BODI's Operating Margin of 3.18% is in line compared to the rest of the industry. BODI outperforms 52.05% of its industry peers.
  • The Gross Margin of BODI (73.01%) is better than 89.04% of its industry peers.
  • BODI's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 3.18%
PM (TTM) N/A
GM 73.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.99%
GM growth 5Y0.54%
BODI Yearly Profit, Operating, Gross MarginsBODI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

3

2. BODI Health Analysis

2.1 Basic Checks

  • BODI has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for BODI has been increased compared to 1 year ago.
  • BODI has less shares outstanding than it did 5 years ago.
  • BODI has a worse debt/assets ratio than last year.
BODI Yearly Shares OutstandingBODI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
BODI Yearly Total Debt VS Total AssetsBODI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -4.03, we must say that BODI is in the distress zone and has some risk of bankruptcy.
  • BODI has a Altman-Z score of -4.03. This is in the lower half of the industry: BODI underperforms 73.97% of its industry peers.
  • The Debt to FCF ratio of BODI is 1.36, which is an excellent value as it means it would take BODI, only 1.36 years of fcf income to pay off all of its debts.
  • BODI has a better Debt to FCF ratio (1.36) than 84.93% of its industry peers.
  • A Debt/Equity ratio of 0.72 indicates that BODI is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.72, BODI is not doing good in the industry: 61.64% of the companies in the same industry are doing better.
  • Although BODI's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF 1.36
Altman-Z -4.03
ROIC/WACC1.07
WACC9.79%
BODI Yearly LT Debt VS Equity VS FCFBODI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M

2.3 Liquidity

  • A Current Ratio of 0.74 indicates that BODI may have some problems paying its short term obligations.
  • BODI has a Current ratio of 0.74. This is in the lower half of the industry: BODI underperforms 72.60% of its industry peers.
  • BODI has a Quick Ratio of 0.74. This is a bad value and indicates that BODI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BODI has a Quick ratio of 0.63. This is in the lower half of the industry: BODI underperforms 79.45% of its industry peers.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.63
BODI Yearly Current Assets VS Current LiabilitesBODI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

3

3. BODI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 95.08% over the past year.
  • Looking at the last year, BODI shows a very negative growth in Revenue. The Revenue has decreased by -39.89% in the last year.
  • BODI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -21.85% yearly.
EPS 1Y (TTM)95.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.09%
Revenue 1Y (TTM)-39.89%
Revenue growth 3Y-28.62%
Revenue growth 5Y-21.85%
Sales Q2Q%-35.7%

3.2 Future

  • BODI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 117.09% yearly.
  • Based on estimates for the next years, BODI will show a small growth in Revenue. The Revenue will grow by 3.38% on average per year.
EPS Next Y6.14%
EPS Next 2Y117.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-11.3%
Revenue Next 2Y3.38%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BODI Yearly Revenue VS EstimatesBODI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
BODI Yearly EPS VS EstimatesBODI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

3

4. BODI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BODI. In the last year negative earnings were reported.
  • Also next year BODI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BODI Price Earnings VS Forward Price EarningsBODI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

  • 94.52% of the companies in the same industry are more expensive than BODI, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BODI indicates a rather cheap valuation: BODI is cheaper than 97.26% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 4.81
EV/EBITDA 2.53
BODI Per share dataBODI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BODI's earnings are expected to grow with 117.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y117.09%
EPS Next 3YN/A

0

5. BODI Dividend Analysis

5.1 Amount

  • BODI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

BODI Fundamentals: All Metrics, Ratios and Statistics

BEACHBODY CO INC/THE

NASDAQ:BODI (3/23/2026, 8:00:01 PM)

11.635

+0.47 (+4.26%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)03-10
Earnings (Next)05-12
Inst Owners38.53%
Inst Owner ChangeN/A
Ins Owners5.22%
Ins Owner Change10.77%
Market Cap83.54M
Revenue(TTM)251.73M
Net Income(TTM)-2.86M
Analysts80
Price Target10.37 (-10.87%)
Short Float %4.75%
Short Ratio4.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)390.11%
Min EPS beat(2)209.89%
Max EPS beat(2)570.32%
EPS beat(4)4
Avg EPS beat(4)209.42%
Min EPS beat(4)14.53%
Max EPS beat(4)570.32%
EPS beat(8)6
Avg EPS beat(8)103.46%
EPS beat(12)7
Avg EPS beat(12)62.06%
EPS beat(16)8
Avg EPS beat(16)37.36%
Revenue beat(2)2
Avg Revenue beat(2)3.78%
Min Revenue beat(2)1.13%
Max Revenue beat(2)6.43%
Revenue beat(4)4
Avg Revenue beat(4)6.37%
Min Revenue beat(4)1.13%
Max Revenue beat(4)10.54%
Revenue beat(8)6
Avg Revenue beat(8)3.49%
Revenue beat(12)8
Avg Revenue beat(12)2.8%
Revenue beat(16)10
Avg Revenue beat(16)2.39%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-17.78%
EPS NQ rev (3m)-17.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-8.94%
Revenue NQ rev (3m)-8.94%
Revenue NY rev (1m)-9.92%
Revenue NY rev (3m)-9.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF 4.81
P/OCF 3.84
P/B 2.67
P/tB N/A
EV/EBITDA 2.53
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)2.42
FCFY20.77%
OCF(TTM)3.03
OCFY26.04%
SpS35.06
BVpS4.36
TBVpS-5.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.95%
ROE -9.13%
ROCE 13.25%
ROIC 10.47%
ROICexc 29.53%
ROICexgc N/A
OM 3.18%
PM (TTM) N/A
GM 73.01%
FCFM 6.89%
ROA(3y)-32.71%
ROA(5y)-35.55%
ROE(3y)-149.3%
ROE(5y)-119.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.99%
GM growth 5Y0.54%
F-Score5
Asset Turnover1.71
Health
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF 1.36
Debt/EBITDA 0.88
Cap/Depr 25.06%
Cap/Sales 1.75%
Interest Coverage 3.03
Cash Conversion 85.09%
Profit Quality N/A
Current Ratio 0.74
Quick Ratio 0.63
Altman-Z -4.03
F-Score5
WACC9.79%
ROIC/WACC1.07
Cap/Depr(3y)15.03%
Cap/Depr(5y)35.29%
Cap/Sales(3y)1.36%
Cap/Sales(5y)3.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.09%
EPS Next Y6.14%
EPS Next 2Y117.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-39.89%
Revenue growth 3Y-28.62%
Revenue growth 5Y-21.85%
Sales Q2Q%-35.7%
Revenue Next Year-11.3%
Revenue Next 2Y3.38%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y120.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year563.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y976.31%
FCF growth 3YN/A
FCF growth 5Y-5.89%
OCF growth 1Y748.95%
OCF growth 3YN/A
OCF growth 5Y-18.75%

BEACHBODY CO INC/THE / BODI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BEACHBODY CO INC/THE (BODI) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BODI.


Can you provide the valuation status for BEACHBODY CO INC/THE?

ChartMill assigns a valuation rating of 3 / 10 to BEACHBODY CO INC/THE (BODI). This can be considered as Overvalued.


How profitable is BEACHBODY CO INC/THE (BODI) stock?

BEACHBODY CO INC/THE (BODI) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for BODI stock?

The Earnings per Share (EPS) of BEACHBODY CO INC/THE (BODI) is expected to grow by 6.14% in the next year.